Preoperative Chemotherapy May Improve Margin-negative Resection Rates, Survival Outcomes in Pancreatic Cancer

Newsfeed Image, Light Gray Text On Dark Gray Background
Preoperative fluorouracil, irinotecan, plus oxaliplatin (FOFIRINOX) followed by chemoradiotherapy leads to high rates of margin-negative (R0) resection and improved survival outcomes among patients with borderline resectable pancreatic cancer, according to a study published in JAMA Oncology.

In a single-arm phase 2 study (ClinicalTrials.gov Identifier: NCT01591733), researchers enrolled 50 previously untreated patients with newly diagnosed and borderline resectable pancreatic cancer. Patients were treated with 8 cycles of neoadjuvant FOLFIRINOX, and if there was no evidence of vascular involvement during restaging, patients received a short course of chemoradiotherapy; patients whose vascular involvement was not resolved received a longer course of chemoradiotherapy. Surgery was performed 1 to 3 weeks after the completion of radiotherapy. The median follow-up was 18 months. Read more . . .